公开(公告)号：US20220213074A1

公开(公告)日：2022-07-07

申请号：US17610662

申请日：2020-05-13

Applicant: H. Lundbeck A/S

Inventor： Cheryl A. GRICE ,  Jeanne V. MOODY ,  Daniel J. BUZARD ,  Justin S. CISAR

IPC: C07D405/14 ,  C07D213/75

Abstract: Provided herein are compounds and compositions useful as modulators of ABHD12. Furthermore, the subject compounds and compositions are useful as immunotherapies in treating, for instance, cancer or infectious diseases.

公开(公告)号：US20240018120A1

公开(公告)日：2024-01-18

申请号：US18252611

申请日：2021-11-12

Applicant: H. LUNDBECK A/S

Inventor： John J.M. WIENER ,  Cheryl A. GRICE ,  Daniel J. BUZARD ,  Justin S. CISAR ,  Olivia Delene WEBER ,  Amy ALLAN ,  Nicholas RAFFAELE ,  Jeanne V. MOODY ,  Michael B. SHAGHAFI

IPC: C07D401/12 ,  C07D405/12 ,  C07D413/12 ,  C07D401/14 ,  C07D487/04 ,  C07D471/04 ,  C07D221/20 ,  C07D417/12 ,  A61P29/00 ,  A61P25/08

CPC classification number: C07D401/12 ,  C07D405/12 ,  C07D413/12 ,  C07D401/14 ,  C07D487/04 ,  C07D471/04 ,  C07D221/20 ,  C07D417/12 ,  A61P29/00 ,  A61P25/08

Abstract: Provided herein are substituted 1,1,1,3,3,3-hexafluoropropan-2-yl 6-azaspiro[2.5]octane-6-carboxylate compounds and pharmaceutical compositions comprising said compounds. The compounds and compositions provided herein are useful as inhibitors of MAGL. Furthermore, the compounds and compositions as provided herein are useful for the treatment of diseases and disorders benefiting from the inhibition of MAGL.

公开(公告)号：US20230357190A1

公开(公告)日：2023-11-09

申请号：US18311759

申请日：2023-05-03

Applicant: H. LUNDBECK A/S

Inventor： Thomas VETTER ,  John J.M. WIENER ,  Cheryl A. GRICE ,  Daniel J. BUZARD ,  Justin S. CISAR ,  Olivia Delene WEBER ,  Amy ALLAN ,  Nicholas RAFFAELE ,  Jeanne V. MOODY ,  Michael B. SHAGHAFI

IPC: C07D401/12

CPC classification number: C07D401/12 ,  C07B2200/13

Abstract: Described herein is new crystalline forms of the MAGL inhibitor 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate.

公开(公告)号：US20230312499A1

公开(公告)日：2023-10-05

申请号：US18053582

申请日：2022-11-08

Applicant: H. Lundbeck A/S ,  THE SCRIPPS RESEARCH INSTITUTE

Inventor： Justin S. CISAR ,  Cheryl A. GRICE ,  Todd K. JONES ,  Micah J. NIPHAKIS ,  Jae Won CHANG ,  Kenneth M. LUM ,  Benjamin F. CRAVATT

IPC: C07D295/205 ,  C07C271/12 ,  C07D317/46 ,  C07D317/58 ,  C07D231/12 ,  C07D231/16 ,  C07D231/56 ,  C07D241/04 ,  C07D471/04 ,  C07D471/10 ,  C07D261/08 ,  C07D487/04 ,  C07D263/32 ,  C07D205/04 ,  C07D491/107 ,  C07D207/14 ,  C07D271/06 ,  C07D307/79 ,  C07D405/14 ,  C07D215/42 ,  C07D213/40 ,  A61P25/22 ,  C07D295/26 ,  C07D213/55 ,  C07D401/04 ,  C07D407/06 ,  C07D413/06 ,  C07C271/10 ,  C07D207/09 ,  C07D213/38 ,  C07D215/46 ,  C07D401/10 ,  C07D403/10 ,  C07D413/10

CPC classification number: C07D295/205 ,  C07C271/12 ,  C07D317/46 ,  C07D317/58 ,  C07D231/12 ,  C07D231/16 ,  C07D231/56 ,  C07D241/04 ,  C07D471/04 ,  C07D471/10 ,  C07D261/08 ,  C07D487/04 ,  C07D263/32 ,  C07D205/04 ,  C07D491/107 ,  C07D207/14 ,  C07D271/06 ,  C07D307/79 ,  C07D405/14 ,  C07D215/42 ,  C07D213/40 ,  A61P25/22 ,  C07D295/26 ,  C07D213/55 ,  C07D401/04 ,  C07D407/06 ,  C07D413/06 ,  C07C271/10 ,  C07D207/09 ,  C07D213/38 ,  C07D215/46 ,  C07D401/10 ,  C07D403/10 ,  C07D413/10

Abstract: This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from post-traumatic stress disorder comprising administering a disclosed compound or composition.

公开(公告)号：US20220153721A1

公开(公告)日：2022-05-19

申请号：US17524632

申请日：2021-11-11

Applicant: H. LUNDBECK A/S

Inventor： John J.M. WIENER ,  Cheryl A. GRICE ,  Daniel J. BUZARD ,  Justin S. CISAR ,  Olivia Delene WEBER ,  Amy ALLAN ,  Nicholas RAFFAELE ,  Jeanne MOODY ,  Michael B. SHAGHAFI

IPC: C07D401/12 ,  C07D405/12 ,  C07D413/12 ,  C07F9/6558 ,  C07D401/14 ,  C07D221/20 ,  C07D487/04 ,  C07D471/04 ,  C07D417/12 ,  A61P25/08 ,  A61P25/04

Abstract: Provided herein are substituted 1,1,1,3,3,3-hexafluoropropan-2-yl 6-azaspiro[2.5]octane-6-carboxylate compounds and pharmaceutical compositions comprising said compounds. The compounds and compositions provided herein are useful as inhibitors of MAGL. Furthermore, the compounds and compositions as provided herein are useful for the treatment of diseases and disorders benefiting from the inhibition of MAGL.